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The possibility of performing genotypic tropism testing (GTT) with proviral DNA (pvDNA) even during suppressed viremia
would facilitate the use of CCR5 inhibitors as part of switching, simplification, or intensification strategies. Thus, we aimed to
evaluate the tropism concordance between plasma RNA and pvDNA samples and to assess which factors could affect possible
discrepancies between the two compartments. GTT was performed using both plasma RNA and pvDNA from 55 sample pairs
from drug-experienced patients. Potential differences between the two compartments were evaluated by analyzing coreceptor
usage and genetic variability. Paired samples were also stratified in three levels of viremia (<50, 51 to 500, and>500 copies/ml).
Overall, Geno2Pheno comparisons of false-positive rates in the two compartments showed good correlation (r 0.72). A high
level of concordance in tropism predictions for the two compartments was found (46/55 sample pairs [83.6%]). Among the 9
sample pairs with discordant tropisms, a larger proportion of pvDNA samples harboring CXCR4/dual-mixed-tropic viruses was
found, in comparison with plasma RNA samples (88.9% versus 11.1%; P 0.0034). Discordant samples were characterized by
greater genetic variability than were concordant samples. With stratification of the paired samples according to viremia levels,
the prevalence of discordant samples decreased with increasing viremia (<50 copies/ml, 21.4%; 51 to 500 copies/ml, 15.4%;
>500 copies/ml, 6.7%; P 0.2). Our findings confirm that prediction of viral tropism using pvDNA is feasible even in low-level
viremia and provides useful information for therapy optimization for patients with low or suppressed viremia.
Human immunodeficiency virus type 1 (HIV-1) requires con-tact with secondary coreceptors (chemokine receptors) to
start infection. CCR5 (R5) and CXCR4 (X4) coreceptors are the
major cellular coreceptors involved in the entry ofHIV-1 into host
cells. Pure R5-tropic and pure X4-tropic viruses can use only
CCR5 and CXCR4 coreceptors, respectively, to enter target cells
(1, 2), while dual-tropic virus can use both coreceptors. In a virus
population, the use of both coreceptors can be due to the presence
of either dual-tropic clones or a mixture of pure R5-tropic and
X4-tropic clones, or both. This is cumulatively defined as a dual/
mixed phenotype (3).
Maraviroc (MVC) is the first R5 antagonist approved for the
treatment of patients already experiencing virological failure be-
cause of resistance to other antiretroviral agents (4, 5). In the
context of virological suppression, regimen switching to MVC is
now feasible. Coreceptor usage in virologically suppressed pa-
tients can be determined from proviral DNA (pvDNA) obtained
from peripheral blood mononuclear cells (PBMCs) (6).
Themajor viral determinant of HIV-1 tropism is the V3 region
of the envelope protein gp120; therefore, analysis of the V3 loop
sequence with genotypic tropism testing (GTT) is of clinical rele-
vance (7). GTT is performed using plasma HIV-1 RNA in clinical
practice but in some settings, such as cases with very low or unde-
tectable viral loads or a lack of plasma, pvDNAmay be considered
a potential alternative source of viral genetic material for tropism
testing (8). Plasma viral RNA represents currently replicating
HIV-1, while pvDNA is intracellular viral DNA that contains the
reservoir of archived viruses (9–11). It has been shown that there
are high frequencies of X4-tropic or dual-tropic viruses in pvDNA
that could persist for long periods (12). Therefore, the possibility
of performing GTT with pvDNA would facilitate the use of R5
antagonists as part of switching, simplification, or intensification
strategies, even during suppressed viremia (13–15). Recent studies
have demonstrated that the performance of V3 region sequencing
with both plasma RNA and pvDNA is very successful, even if the
performance of pvDNA is higher than that of plasma RNA, espe-
cially in the setting of low-level viremia (93.3% and 63%, respec-
tively) (3, 16), confirming that GTT with pvDNA is feasible and
significantly relevant. Although the use of MVC after DNA tro-
pism testing has potential, this strategy is not yet recommended
in current guidelines, because of the lack of large studies on this
topic (6).
Several studies showed a high level of concordance between
HIV-1 genotypic coreceptor tropism predictions based on plasma
RNA and pvDNA findings (2, 11, 17–19), but the factors that
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might be associated with the discrepancies between the two
compartments have not yet been clearly determined. More-
over, little is known about the tropism concordance between
the two compartments in patients with virological suppression
(viremia levels of 50 copies/ml).
Thus, the aim of this study was to analyze the degree of GTT
concordance between plasma HIV-1 RNA and pvDNA overall
and according to different viremia levels (including low or unde-
tectable viremia values). Moreover, the factors that may affect the
discrepancies between the two compartments were evaluated.
(Thisworkwas presented in part at the 6thNationalWorkshop
of the Società Italiana Virologia Medica, Rome, Italy, 10 to 12
December 2014.)
MATERIALS AND METHODS
Patients. This retrospective study included samples from HIV-1-drug-
experienced subjects that had been tested for the V3 loop region of gp120
in both pvDNA and plasma HIV-1 RNA in 2010 to 2014, in three clinical
centers in Italy, in routine clinical practice. Patients selected had paired
samples with blood sampling dates that were concomitant or within a
period of 24 months at most, on the basis of the observation that no
evolution is found in samples within 24 months of follow-up monitoring
(20). For each sample, the viremia value at the time of genotyping was
known.
Viral RNA/DNA extraction. Viral RNA was extracted from 1 ml of
plasma samples, as described previously (21). Proviral DNAwas obtained
from lymphomonocytic cells after separation from peripheral blood from
HIV-1-infected patients with a Ficoll-Hypaque gradient, as described pre-
viously (22). HIV-1DNAwas extracted fromPBMCs by using a commer-
cially available kit (QIAampDNAViralminikit; Qiagen), according to the
product specifications.
PCR amplifications and sequencing. The V3 region of the env gene
was amplified using a homemade one-step reverse transcription (RT)-
PCR system (for viral RNA samples) or PCR (for viral DNA samples).
When theRT-PCRproductwas not visible on an agarose gel, a nested PCR
was performed as described previously (3, 16).
PCR products were then subjected to full-length sequencing in the
sense and antisense orientations by using the BigDye Terminator version
3.1 cycle sequencing kit (Applied Biosystems) and an automated se-
quencer (ABI 3130). Sequences with a mixture of wild-type and mutant
residues at a single position were considered to have a mutation at that
position.Whenmixtures contained at least two different mutations, all of
the mutations were considered and the sequences were reported as qua-
sispecies.
Phylogenetic analysis.Aphylogenetic analysis ofHIV-1V3 sequences
was performed for the following purposes: (i) to determine viral subtypes,
(ii) to check for any cross-contamination, and (iii) to evaluate the proper
clustering of the pvDNA and plasma RNA sequences from the same sub-
jects. Briefly, the V3 sequences were aligned with HIV-1 reference se-
quences of all subtypes (http://www.hiv.lanl.gov). The alignment was ed-
ited using the BioEdit program, version 7.0.5.3. MEGA6 (23) was used to
perform phylogenetic analysis. A first phylogenetic tree was constructed
with a neighbor-joining (NJ) method. Distances were calculated using
MEGA6, based on the Kimura 2-parameter (K2P) model (24). The reli-
ability of the branching orders was assessed by bootstrap analysis of 1,000
replicates.
The robustness of the paired sample clusters was further tested using
the maximum likelihood (ML) method. This was inferred with the gen-
eralized time-reversible (GTR) nucleotide substitution model, with
gamma distribution of rates among site heterogeneity, a proportion of
invariable sites (GTR  I  5) (25), and 1,000 bootstrap replicates.
Paired sample clusters were identified by bootstrap support of 70%.
FigTree software was used to draw trees. HIV-1 subtypes were confirmed
by analyzing HIV-1 pol (protease/reverse transcriptase) sequences ob-
tained from the same samples, by repeating the phylogenetic analysis and
by using the REGA subtype tool (http://www.bioafrica.net/rega-genotype
/html/subtypinghiv.html) and the COMET subtype tool (http://comet
.retrovirology.lu). To improve the accuracy of recombinant and unique
forms, RDP3 software (http://web.cbio.uct.ac.za/darren/rdp.html) and
Splits Tree software (http://en.bio-soft.net/tree/SplitsTree.html) were
used.
Tropism determination. HIV-1 coreceptor usage was inferred from
the V3 nucleotide sequence by using the Geno2Pheno (G2P) algorithm
(http://coreceptor.bioinf.mpi-inf.mpg.de). For plasma RNA samples,
G2P was set at a false-positive rate (FPR) of 10%, according to guidelines
on the clinical management of HIV-1 tropism testing (8). For pvDNA
samples, G2P was set at FPR values of both 10%, as reported in several
studies (2, 11, 18, 26, 27), and 20%, as recommended by guidelines (8).
Thus, sequences with FPRs of10% from both plasma RNA and pvDNA
samples and 20% from pvDNA samples were considered X4/dual-
mixed tropic. The concordance of genotypically inferred tropism patterns
was evaluated for each sample pair.
Evaluation of V3 variability. Pairwise genetic distance analyses were
conducted using the Tajima-Nei model (28). The rate variation among
sites was modeled with a gamma distribution (shape parameter  0.5).
The analysis involved 110 nucleotide sequences. The codon positions in-
cludedwere first plus second plus third plus noncoding. All positions with
95% site coverage were eliminated. That is,5% alignment gaps, miss-
ing data, and ambiguous bases were allowed at any position. Evolutionary
analyses were conducted with MEGA6 (23).
Statistical analysis. All analyses were performed using the statistical
software package SPSS (version 19.0) for Windows (SPSS Inc., Chicago,
IL). P values of0.05 were considered statistically significant.
Evaluation of potential differences between pvDNA and RNA sam-
ples. Potential differences among DNA and RNA paired samples were
evaluated with the Mann-Whitney test for continuous variables (such as
viral loads, CD4 cell counts, FPRs, genetic distances, numbers of mu-
tated positions, and numbers of quasispecies) and with Fisher’s exact test
for categorical variables (such as the proportions of sampleswithX4/dual-
mixed-tropic viruses). Spearman’s correlation coefficient (r) was used to
study the correlation of FPRs determined from genotypic tropism testing
of RNA and pvDNA samples.
Evaluation of tropism concordance between compartments in dif-
ferent viremia ranges. The concordance of tropism results for the two
compartments was also evaluated according to different levels of viremia.
Paired samples were divided according to viremia ranges of 50 copies/
ml, 51 to 500 copies/ml, or500 copies/ml. This analysis was restricted to
the 42 pairs of samples belonging to the same viremia range. The chi-
squared test for trend was used to evaluate potential differences in the
concordances for the different viremia ranges.
Evaluation of V3 mutation prevalence in DNA and RNA samples
according to tropism. Among the concordant paired samples, the asso-
ciation of V3 mutations with genotypically determined tropism was eval-
uated. For this analysis, paired samples were divided into two groups
(X4/dual-mixed group andR5 group) according to the tropism. The prev-
alence of eachV3mutationwas calculated for each group, and results were
compared for pvDNA and RNA samples. Potential differences in the mu-
tation prevalence between DNA and RNA samples were calculated by
using Fisher’s exact test. All mutations found at the 35 V3 positions with
an overall prevalence of10% were evaluated.
RESULTS
Study population. Samples from a total of 55 HIV-1-drug-expe-
rienced subjects were analyzed; 37 patients had concomitant
paired samples, while 18 had paired samples collected within a
period of 1 to 11 months. Demographic and clinical characteris-
tics of patients at the time of pvDNA genotyping are presented in
Table 1.
The population was mainly represented by male (69.1%) and
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Italian (80%) subjects. Phylogenetic analysis of the V3 sequences
revealed that the B subtype was themost prevalent strain (78.2%).
The remaining 21.8% of patients were infected with non-B-sub-
type viruses (3 C, 3 BF, 2 F1, 2 G, 1 BC, and 1 CRF06_cpx). Phy-
logenetic analysis of the pol sequences confirmed the subtypes
determined with V3 sequences.
Overall, at the time of sample collection, median viremia levels
were 3.32 log10 copies/ml (interquartile range [IQR], 2.36 to 4.8
log10 copies/ml) and 1.72 log10 copies/ml (IQR, 1.60 to 2.14 log10
copies/ml) for RNA andDNA samples, respectively. In particular,
for the nonconcomitant samples, the plasma viral load was signif-
icantly higher for RNA samples (medians of 2.10 log10 copies/ml
[IQR, 1.71 to 3.0 log10 copies/ml] and 1.60 log10 copies/ml [IQR,
1.37 to 1.98 log10 copies/ml] for RNA and DNA samples, respec-
tively; P 0.006).
Median CD4 cells counts at the time of sample collection
were 375 cells/mm3 (IQR, 233 to 615 cells/mm3) and 375 cells/
mm3 (IQR, 262 to 714 cells/mm3) for RNA and DNA samples,
respectively. Of note, no difference in CD4 cell counts was found
between concomitant and nonconcomitant samples (medians of
375 cells/mm3 [IQR, 267 to 590 cells/mm3] and 338 cells/mm3
[IQR, 234 to 682 cells/mm3], respectively; P 0.92).
Seven patients had received MVC; of those patients, five con-
tinued to receive MVC at the time of pvDNA sampling. All other
patients were naive to MVC.
V3 genotyping reliability. By evaluating each cluster with the
paired plasmaRNAandpvDNA samples, we found that sequences
belonging to the same subject showed a high level of homology
(bootstrap value of 70%) in 100% of cases, denoting genetic
relatedness (see Fig. S1 in the supplemental material).
Characterization of HIV-1 tropism, viremia, and genetic di-
versity in paired plasma RNA and pvDNA samples.Overall, set-
ting the FPR at 10%, a genotypically inferred tropism concor-
dance between compartments was found for 46/55 samples
(83.6%) (Fig. 1A). R5 tropism was predicted for 38/46 sample
pairs (82.6%), with FPRs ranging from 13.0% to 96.1%; X4/dual-
mixed tropismwas predicted for 8/46 samples (17.4%), with FPRs
ranging from 0.2% to 8.6%. The concordance of tropism findings
was very high among concomitant samples (92.0% [34/37 sam-
ples]) (Fig. 1B) andwas still considerable among nonconcomitant
samples (66.7% [12/18 samples]) (Fig. 1C). The proportion of
X4/dual-mixed-tropic viruses in discordant samples was signifi-
cantly greater for pvDNA samples than for plasma RNA samples,
as expected (8/9 samples [88.9%] versus 1/9 samples [11.1%]; P
0.0034, by Fisher’s exact test). Overall, most of the discordant
samples had nonconcomitant sampling dates, in a range of 30 to
256 days, and were characterized by greater differences in FPRs
between plasma RNA and pvDNA samples than were concordant
samples (median FPR values of 20.0% [IQR, 11.0 to 52.0%]
versus 1.0% [IQR, 0.0 to 7.6%]; P  0.001) (Fig. 1A). A higher
FPR in discordant samples was also found by repeating the anal-
ysis within concomitant and nonconcomitant samples (Fig. 1B
and C). Four (44.4%) of nine pairs of discordant samples be-
longed to patients infectedwith non-B-subtype viruses (1 BC, 1G,
and 2 F1). Of note, no patient treated with MVC had discordant
tropisms in the two compartments.
Overall, among the patients analyzed, lower viremia levels were
found for those with discordant samples than for those with con-
cordant samples (medians of 1.73 log10 copies/ml [IQR, 1.60 to
2.02 log10 copies/ml] versus 2.26 log10 copies/ml [IQR, 1.92 to
4.12 log10 copies/ml]; P  0.036) (Fig. 1A). This difference was
maintained even when concomitant and nonconcomitant sam-
ples were analyzed separately (Fig. 1B and C). No difference in
CD4 cell counts was found between concordant and discordant
samples (medians of 379 cells/mm3 [IQR, 264 to 637 cells/mm3] and
358 cells/mm3 [IQR, 240 to 691 cells/mm3], respectively; P 0.98).
To evaluate the pairwise genetic variability between the two
compartments, genetic distances, in terms of the number of base
substitutions per site, were calculated (Fig. 1). Data showed
greater genetic variability in discordant samples than in concor-
dant samples (median genetic distances of 0.00 [IQR, 0.00 to 0.02]
versus 0.07 [IQR, 0.02 to 0.23]; P 0.001) (Fig. 1A).
Numbers of quasispecies and mutated positions were also an-
TABLE 1 Patient characteristics at the time of pvDNA V3 genotyping
Characteristica Value
No. of patients 55
Male (no. [%]) 38 (69.1)
Age (median [IQR]) (yr) 50 (43–55)
Nationality (no. [%])
Italian 44 (80.0)
African 6 (10.9)
Other 5 (9.1)
HIV exposure (no. [%])
Heterosexual sex 17 (30.9)
MSM 12 (21.8)
IDU 6 (10.9)
Unknown or other 20 (36.4)
Subtype (no. [%])
B 43 (78.2)
Non-Bb 12 (21.8)
CD4 cell count (median [IQR]) (cells/mm3)
At RNA sequencing 375 (233–615)
At DNA sequencing 375 (262–714)
Past drug treatment (no. [%])
NRTI 53 (96)
NNRTI 29 (53)
PI 51 (93)
INI 17 (31)
Enfuvirtide 3 (5.4)
Maraviroc 7 (12.7)
Treatment status (no. [%])
Receiving treatment 48 (87.3)
In treatment interruption 7 (12.7)
Current drug treatment (no. [%])c
NRTI 42 (76.4)
NNRTI 13 (24)
PI 31 (56.4)
INI 10 (18)
Enfuvirtide 5 (9)
Maraviroc 5 (9)
a MSM, men having sex with men; IDU, injection drug use; NRTI, nucleotide reverse
transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; INI, integrase inhibitor.
b C (n 3), BF (n 3), F1 (n 2), G (n 2), BC (n 1), or CRF06_cpx (n 1).
c Six (10.9%) of 55 patients were undergoing different treatments at the time of RNA
genotyping versus the time of pvDNA genotyping.
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alyzed. Substantial similarity among the numbers of mutated po-
sitions between plasma RNA and pvDNA was found (medians of
7 positions [IQR, 5 to 9 positions] and 6 positions [IQR, 5 to 8
positions], respectively; P 0.82), while, as expected, the number
of quasispecies increased in pvDNA (medians of 0 quasispecies
[IQR, 0 to 4 quasispecies] for RNA sequences and 4 quasispecies
[IQR, 0 to 8 quasispecies] for DNA sequences; P 0.008).
Comparison of the overall G2P FPRs in plasma RNA and
pvDNA compartments showed good correlation (r  0.72; P 
0.001) (Fig. 2A). A very good correlation was found for the 37
concomitant samples (r 0.93;P 0.001) (Fig. 2B), while a lower
correlation was found among the 18 nonconcomitant samples
(r  0.37; P  0.046) (Fig. 2C), which was explained by a large
difference in FPRs between the 2 compartments (median of 7.3%
[IQR, 0.2 to 43.5%]).
With the FPR set at 20% for pvDNA samples, as suggested by
the European guidelines on the clinical management of HIV-1
tropism testing (8), the number of discordant pairs of samples
increased from nine to 16 (29%). Of note, the difference between
FPRs for the two compartments for the additional seven discor-
dant couples with FPRs in the range 10 to 20% was very low (me-
dian FPR of 0.0% [IQR, 0.0 to 8.4%]).
Evaluation of tropism concordance between compartments
at different viremia levels. The concordance of tropism findings
FIG 1 Characterization of HIV-1 tropism, viremia, and genetic diversity for paired RNA and DNA samples. Percentages of concordant and discordant samples
for the overall paired samples (A), the concomitant paired samples (B), and the nonconcomitant paired samples (C) are shown. Potential differences among
paired RNA and DNA samples were evaluated with the Mann-Whitney test.
FIG 2 Scatterplots for comparisons between plasma RNA and pvDNAV3-based coreceptor tropism predictions. Tropism predictions were performed with the
Geno2Pheno (G2P) coreceptor tool, and results are expressed as the false-positive rate (FPR). Correlation coefficients are shown for the overall samples (A), for
the 37 concomitant samples (B), and for the 18 nonconcomitant samples (C).
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for the two compartments was evaluated according to the viremia
levels. Among the 42 sample pairs with the same viremia levels,
33.3%, 31%, and 35.7% had viremia levels of50, 51 to 500, and
500 copies/ml, respectively. With stratification of the paired
samples according to the viremia levels, the prevalence of discor-
dant samples increasedwith decreasing viremia, althoughwithout
statistical significance, probably due to the small numbers of sam-
ples analyzed for each group (50 copies/ml, 21.4%; 51 to 500
copies/ml, 15.4%;500 copies/ml, 6.7%; P 0.2, by chi-squared
test for trend) (Fig. 3). In considering the tropism of concordant
paired samples (36/42 samples [85.7%]), the prevalence of X4/
dual-mixed tropism was higher for viremia values of 50 cop-
ies/ml than for viremia values of 50 copies/ml (4/11 samples
[36.4%] versus 2/25 samples [8.0%]; P 0.052).
Evaluation ofV3mutation prevalence in pvDNAandplasma
RNA samples according to tropism. Among the concordant
paired samples (n  46), the prevalence of V3 mutations was
evaluated in X4/dual-mixed and R5 paired samples. Among the
X4/dual-mixed paired samples (n  8), the V3 mutations S11G
(61.5%), H13R (37.5%), E25R (50.0%), Q32K (37.5%), and
H34Y (50.0%) were found with greater prevalence in pvDNA
samples. In contrast, the V3 mutations N5D (37.5%), K10R
(62.5%), H13S (37.5%), T22A (75.0%), G24R (37.5%), E25K
(62.5%), and I26V (62.5%)weremostly prevalent in plasmaRNA,
suggesting different viral evolution in the two compartments (see
Fig. S2A in the supplemental material). These differences in mu-
tation prevalence did not have any statistical significance, how-
ever, probably due to the small number of samples. No difference
between the two compartments in the mutation prevalence was
found in R5-tropic concordant samples (n 38) (see Fig. S2B in
the supplemental material).
DISCUSSION
In this study, we aimed at evaluating the genotypically inferred
tropism in paired plasma HIV-1 RNA and pvDNA samples from
55 HIV-1-infected patients. In particular, we characterized the
tropism concordance between the two compartments overall and
according to viremia levels. Patients with viremia levels of 50
copies/ml in both plasma RNA and pvDNA samples were also
analyzed, whereas the great majority of the previous studies did
not compare the two compartments in the undetectable range of
viremia but focused their attention on plasma HIV-1 RNA sam-
ples from patients with detectable viral loads (11, 18, 29, 30).
We found a high level of concordance between the two com-
partments (84%), confirming findings described previously in
other studies (2, 11, 17, 18).With the FPR set at 10%, concordance
was found mainly for R5-tropic viruses (83%). The overall FPR
values were linearly correlated between the two compartments
(r 0.72; P 0.001). In particular, the FPR correlation increased
when we considered only the concomitant samples (r 0.93; P
0.001), while it decreased when we considered nonconcomitant
samples (r  0.37; P  0.046). Discordance was attributable
mainly to X4/dual-mixed prediction from pvDNA samples and
R5 prediction from plasma RNA samples, as found in other stud-
ies (10–12, 26, 31). These findings indicate that, although plasma
and PBMCs often provide similar tropism reports (32), tropism
testing with PBMCsmay not produce biological results equivalent
to those from plasma, because the structures of viral populations
vary between compartments (30), and can be useful in excluding
slightly more individuals from treatment with a CCR5 inhibitor.
In the evaluation of the genetic variability between the two com-
partments, a greater median number of quasispecies in pvDNA
was found with either concomitant or nonconcomitant samples,
with a consistent increase in quasispecies in the latter group. These
findings confirm that V3 pvDNA and RNA populations can be
different, suggesting that archived viruses may not always corre-
spond to the viruses most prevalent in plasma (33). However, the
presence of a larger number of quasispecies could influence the
correct algorithmic interpretation, overestimating the presence of
discordant paired samples.
Most of the discordant paired samples found in our study
(66.7%) had nonconcomitant sampling dates (30 to 256 days
apart), suggesting viral evolution in a short period. Therefore,
simultaneous sample collection should be carried out for proper
comparison of the two compartments. Tropism discordance be-
tween the two compartments could even be due to subtype. In-
deed, 44.4% of discordant pairs were from patients infected with
non-B-subtype viruses. In this regard, it should be noted that es-
timations of HIV-1 tropism using bioinformatics tools based on
V3 sequences are worse for testing non-B strains than for testing B
strains. In particular, G2P is a tool that mainly overestimates X4
predictions for non-B subtypes (34). Therefore, further optimiza-
tion of genotypic methods is needed, and larger studies to deter-
mine the utility of suchmethods for tropismprediction for diverse
HIV-1 non-B subtypes are necessary, especially in light of in-
creased circulation of non-B strains in areas with previously ho-
mogeneous B strains, such as several European countries, includ-
ing Italy (35). In general, discordant samples were foundmostly at
lower viremia levels, compared with concordant samples (median
plasma HIV RNA levels of 1.73 log10 copies/ml [IQR, 1.60 to 2.02
log10 copies/ml] versus 2.26 log10 copies/ml [IQR, 1.92 to 4.12
log10 copies/ml]). With stratification of the paired samples ac-
cording to the viremia level (50, 51 to 500, or500 copies/ml),
the prevalence of discordant samples decreased with increasing
levels of viremia (21.4%, 15.4%, and 6.7%, respectively). Similar
results were found by Verhofstede and colleagues (11). These
findings suggest that, in patients with low-level viremia, viral qua-
sispecies in the plasma compartment did not fully represent the
proviral reservoir.
By analyzing the most prevalent V3 mutations (overall preva-
lence of10%), we confirmed that somemutations are associated
FIG 3 Evaluation of tropism concordance between paired plasma RNA and
pvDNAsamples according to the viremia level, among the 42 sample pairswith
the same viremia levels. P 0.2, by chi-squared test for trend.
Genotypic Tropism Testing in HIV-1 Proviral DNA
September 2015 Volume 53 Number 9 jcm.asm.org 2939Journal of Clinical Microbiology
 o
n
 August 28, 2016 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
with X4 (e.g., E25K [more prevalent in plasma RNA] and E25R,
Q32K, and H34Y [more prevalent in pvDNA]) or R5 (i.e., F20L,
Y21F, T22A, and E25D [similar prevalence rates in the two com-
partments]) coreceptor usages in both compartments (36, 37).
Themain limitations of our studywere the small number of paired
samples included and the heterogeneity of the population (such as
the presence of nonconcomitant and non-B-subtype samples),
which could have yielded overestimations of the differences be-
tween the two compartments.
In conclusion, our findings confirm that GTT produces a rel-
atively good correlation between pvDNA and RNA tropism esti-
mations, suggesting that prediction of viral tropism using PBMC
DNA is feasible. Among discordant samples, the presence of X4/
dual-mixed-tropic viruses in pvDNA in the setting of low viremia
levels suggests that genotypic tropism determinationwith pvDNA
provides useful information for the optimization of therapy for
patients with low-level or suppressed viremia. Further studies are
needed to determine whether the use of MVC for patients with
virological suppression and with discordant tropisms in the two
compartments (R5 in plasma RNA and X4/dual-mixed in
pvDNA) could be effective over time.
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